Marcel Devetten, MD | Authors

HCR MANORCARE

8442 SETTLERS PSGE

Articles

Refractory CML: Not All Forms of Resistance Are Equal

April 15, 2008

The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).